Bimekizumab Long-term Efficacy in Patients with Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 Nov. 7];8(6):s433. Available from: https://skin.dermsquared.com/skin/article/view/3092